Protein C and Protein S Testing Post-Stroke
Testing for protein C and protein S deficiency should be deferred until at least 4-6 weeks after acute stroke, and routine screening is not recommended in most stroke patients unless specific clinical scenarios suggest a hypercoagulable state. 1
When to Consider Testing
Testing for protein C and protein S deficiency should be reserved for specific clinical scenarios, not performed routinely:
- Young patients (typically <45 years) with cryptogenic stroke and no identifiable vascular risk factors
- Personal or family history of unprovoked thrombosis
- History of recurrent spontaneous abortions
- Paradoxical emboli from venous thrombosis (with or without patent foramen ovale)
- Recurrent venous thromboembolism
- Systemic signs suggesting hypercoagulability 1
The 2021 AHA/ASA guidelines emphasize that suspicion for hypercoagulable states varies by clinical scenario and should be considered primarily in younger populations with unexplained stroke 1.
Critical Timing Considerations
The most important pitfall to avoid is testing too early. Protein C and protein S levels are altered during the acute stroke phase, leading to falsely low results 1. This has led to unnecessary anxiety, inappropriate lifelong anticoagulation, and even termination of pregnancies in families where inherited deficiency was not actually confirmed 2.
- Minimum waiting period: 4-6 weeks after acute stroke
- Optimal timing: Up to 6 months for some factors 1
- If abnormal: Repeat testing is mandatory before making any diagnosis of hereditary deficiency 3, 2
Evidence Against Routine Screening
Multiple studies demonstrate that hereditary protein C and protein S deficiencies are rare causes of stroke:
- In 127 consecutive young adults (<45 years) with ischemic stroke, all abnormal levels found were due to acquired causes (pregnancy, estrogen, acute inflammation) or normalized on repeat testing 3
- A study of 33 children with cryptogenic stroke found no confirmed hereditary deficiencies; low levels normalized over months 2
- Among 36 young patients with unexplained stroke, only 25% had any natural anticoagulant deficiency, with protein S being most common (13.8%) 4
Low protein C levels during acute stroke reflect massive coagulation activation and predict worse outcomes, but do not indicate hereditary deficiency 5.
Management Approach
For patients with confirmed protein C or protein S deficiency and stroke:
If the patient has unprovoked deep vein thrombosis with positive thrombophilic testing, follow standard DVT treatment recommendations 1. The stroke mechanism in these cases is typically paradoxical embolism through a cardiac or pulmonary shunt.
Key distinction: The guidelines do not recommend different antithrombotic therapy for stroke patients based solely on protein C or protein S deficiency status. Standard secondary stroke prevention applies unless there is concurrent venous thromboembolism requiring anticoagulation.
What NOT to Do
- Do not test protein C/S levels in the acute stroke period
- Do not diagnose hereditary deficiency based on a single abnormal test
- Do not routinely screen older patients with typical vascular risk factors 1
- Do not assume arterial stroke is directly caused by protein C/S deficiency without considering paradoxical embolism mechanism
- Do not initiate lifelong anticoagulation based solely on low levels without confirmed hereditary deficiency and appropriate clinical context
Practical Algorithm
- Acute stroke patient: Do NOT test protein C/S
- 4-6 weeks post-stroke: Consider testing ONLY if patient meets high-risk criteria (young, cryptogenic, personal/family thrombosis history)
- If abnormal: Repeat testing after 6 months
- If persistently abnormal: Consider genetic testing and family screening
- Treatment: Base on stroke mechanism and standard guidelines, not solely on deficiency status